Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer.
Bratisl Lek Listy
; 123(6): 401-407, 2022.
Article
in English
| MEDLINE | ID: covidwho-1847499
ABSTRACT
OBJECTIVE:
To compare seroconversion for SARS-CoV-2 receptor-binding domain (RBD) specific IgG positivity against two doses of the CoronaVac vaccine in breast and lung cancer patients receiving systemic therapy, to determine the factors affecting seropositivity, and to observe long-term results up to a secondary booster vaccine.RESULTS:
The analysis included 201 cancer patients (99 breasts, 102 lungs; median age 59 years (range 28-92), 42.3 % men) and 97 controls (median age 62 years (range 24-87), 38.1 % men). The seropositivity rate for RBD IgG after 2 doses of vaccine in the cancer group was 81.6 % (n=164) and 93.8 % (n=91) in the control group (p=0.005). The median IgG titer of cancer patients was significantly lower than in the control group (338 (IQR, 95-933) AU/mL vs 676 (IQR, 389-1270) AU/mL; p<0.001). Multivariate analysis of all the patients determined that having cancer (OR 0.303, 95%CI 0.123-0.750, p=0.010) and being over 60 years of age (OR 0.447, 95%CI 0.218-0.917, p=0.028) was associated with a reduced vaccine response. A subgroup analysis of cancer patients revealed that seroconversion was lower in men than in women (75.3 % vs 86.2 %, p=0.049) and lower in ≥60 patients than in <60 patients (75.9 % vs 89.4 %, p=0.014). DISCUSSION ANDCONCLUSION:
Cancer patients receiving an active systemic therapy with two doses of the CoronaVac vaccine had a lower antibody response than the non-cancer population, and deaths due to COVID-19 may occur in these patients despite the vaccine. Therefore, extensive protective measures should be taken to protect against COVID-19 in cancer patients aged 60 years and older, who have received two doses of the CoronaVac vaccine (Tab. 4, Fig. 4, Ref. 27).Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Lung Neoplasms
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Bratisl Lek Listy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS